Vitally, all DSSs focus on the use of exogenous insulin as either an input or output and are therefore of no use to those with a rare hypoglycaemia disorder such as CHI or GSD but may have potential in neonates on insulin therapy (66). This evidence concerns the gene INS and congenital isolated hyperinsulinism.